Modulation of natural killer cell anti-tumor reactivity by platelets

Journal of Innate Immunity

Volumn 3, Issue 4, 2011, Pages 374-382

  Placke, Theresa ^a   Kopp, Hans Georg ^a   Salih, Helmut Rainer ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cancer; Metastasis; Natural killer cells; Platelets

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2D; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; SOMATOMEDIN C; THROMBOCYTE FACTOR 4; VASCULOTROPIN;

CELL INTERACTION; CELL SECRETION; CYTOKINE PRODUCTION; HUMAN; IMMUNOMODULATION; METASTASIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; THROMBOCYTE; THROMBOCYTE COATING; THROMBOCYTE FUNCTION; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; BLOOD PLATELETS; HUMANS; KILLER CELLS, NATURAL; MICE; NEOPLASM METASTASIS; NEOPLASMS; SPECIES SPECIFICITY;

EID: 79959634062     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000323936     Document Type: Review

References (55)

1. Lanier LL: NK cell recognition. Annu Rev Immunol 2005; 23: 225-274.
2. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S: Functions of natural killer cells. Nat Immunol 2008; 9: 503-510.
3. Billroth T: Lectures on Surgical Pathology and Therapeutics: A Handbook for Students and Practitioners. London, New Sydenham Society, 1878.
4. Erpenbeck L, Schon MP: Deadly allies: the fatal interplay between platelets and metas-tasizing cancer cells. Blood 2010; 115: 3427-3436.
5. Gasic GJ, Gasic TB, Stewart CC: Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968; 61:46-52.
6. Nieswandt B, Hafner M, Echtenacher B, Mannel DN: Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295-1300.
7. Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S: Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer 1973; 11: 704-718.
8. Nierodzik ML, Karpatkin S: Thrombin induces tumor growth, metastasis, and angio-genesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006; 10: 355-362.
9. Rickles FR, Falanga A: Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102:V215-V224.
10. Pearlstein E, Salk PL, Yogeeswaran G, Karpatkin S: Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line. Proc Natl Acad Sci USA 1980; 77:4336-4339.
11. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS: Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988; 81: 1012-1019.
12. Karpatkin S, Ambrogio C, Pearlstein E: Lack of effect of in vivo prostacyclin on the development of pulmonary metastases in mice following intravenous injection of CT26 colon carcinoma, Lewis lung carcinoma, or B16 amelanotic melanoma cells. Cancer Res 1984; 44: 3880-3883.
13. Gorelik E, Bere WW, Herberman RB: Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int J Cancer 1984; 33:87-94.
14. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, Hattori K, Zhang F, Hicklin DJ, Wu Y, Zhu Z, Dunn A, Salari H, Werb Z, Hackett NR, Crystal RG, Lyden D, Rafii S: Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006; 12:557-567.
15. Gurney AL, de Sauvage FJ: Dissection of c-Mpl and thrombopoietin function: studies of knockout mice and receptor signal transduction. Stem Cells 1996; 14(suppl 1):116-123.
16. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL: Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105:178-185.
17. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA, Degen JL: Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and -independent mechanisms. Blood 2007; 110:133-141.
18. Zheng S, Shen J, Jiao Y, Liu Y, Zhang C, Wei M, Hao S, Zeng X: Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. Cancer Sci 2009; 100: 859-865.
19. Palumbo JS, Barney KA, Blevins EA, Shaw MA, Mishra A, Flick MJ, Kombrinck KW, Talmage KE, Souri M, Ichinose A, Degen JL: Factor XIII transglutaminase supports he-matogenous tumor cell metastasis through a mechanism dependent on natural killer cell f unction. J Thromb Haemost 2008; 6: 812-819.
20. Skov MP, Hokland P, Hokland M: Secretory products from thrombin-stimulated human platelets exert an inhibitory effect on NK-cy-totoxic activity. Acta Pathol Microbiol Immunol Scand C 1986; 94: 193-200.
21. Howells GL, Macey M, Murrell AM, Green AR, Curtis MA, Stone SR: Thrombin receptor expression and function in large granular lymphocy te proliferative disorders. Br J Haematol 1994; 88:383-388.
22. Naldini A, Carney DH: Thrombin modulation of natural killer activity in human peripheral lymphocytes. Cell Immunol 1996; 172: 35-42.
23. Naldini A, Morena E, Fimiani M, Campoccia G, Fossombroni V, Carraro F: The effects of autologous platelet gel on inflammatory cytokine response in human peripheral blood mononuclear cells. Platelets 2008; 19: 268-274.
24. Kopp HG, Placke T, Salih HR: Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009; 69:7775-7783.
25. Ahamed J, Janczak CA, Wittkowski KM, Coller BS: In vitro and in vivo evidence that thrombospondin-1 (TSP-1) contributes to stirring- and shear-dependent activation of platelet-derived TGF-beta1. PLoS One 2009; 4:e6608.
26. Pierson BA, Gupta K, Hu WS, Miller JS: Human natural killer cell expansion is regulated by thrombospondin-mediated activation of transforming growth factor-beta 1 and independent accessory cell-derived contact a nd soluble factors. Blood 1996; 87: 180-189.
27. Gersuk GM, Westermark B, Mohabeer AJ, Challita PM, Pattamakom S, Pattengale PK: Inhibition of human natural killer cell activity by platelet-derived growth factor (PDGF). 3. Membrane binding studies and differential biological effect of recombinant PDGF isoforms. Scand J Immunol 1991; 33: 521-532.
28. Auernhammer CJ, Feldmeier H, Nass R, Pachmann K, Strasburger CJ: Insulin-like growth factor I is an independent coregulatory modulator of natural killer (NK) cell activity. Endocrinology 1996; 137:5332-5336.
29. Melder RJ, Koenig GC, Witwer BP, Safaba khsh N, Munn LL, Jain R.K: During a ngiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996; 2: 992-997.
30. Wiesner T, Bugl S, Mayer F, Hartmann JT, Kopp HG: Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. Clin Exp Metastasis 2010; 27:141-149.
31. Marti F, Bertran E, Llucia M, Villen E, Peiro M, Garcia J, Rueda F: Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8. J Leukoc Biol 2002; 72: 590-597.
32. Robertson MJ: Role of chemokines in the biology of natural killer cells. J Leukoc Biol 2002; 71: 173-183.
33. Flad HD, Brandt E: Platelet-derived chemokines: pathophysiology and therapeutic aspects. Cell Mol Life Sci 2010; 67: 2363-2386.
34. Klein-Struckmeier A, Knuver-Hopf J, Mohr H: Modulation of natural and interleukin-2-induced tumour-cytolytic activities by the members of a protein family related to beta-thromboglobulin. Cancer Immunol Immunother 1991; 34: 175-180.
35. Italiano JE Jr, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL: Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111:1227-1233.
36. Li N: Platelet-lymphocyte cross-talk. J Leukoc Biol 2008; 83:1069-1078.
37. Kisucka J, Butterfield CE, Duda DG, Eichen-berger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD: Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA 2006; 103: 855-860.
38. Andre P, Spertini O, Guia S, Rihet P, Dignat-George F, Brailly H, Sampol J, Anderson PJ, Vivier E: Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin. Proc Natl Acad Sci USA 2000; 97: 3400-3405.
39. Vivier E, Sorrell JM, Ackerly M, Robertson MJ, Rasmussen RA, Levine H, Anderson P: Developmental regulation of a mucinlike glycoprotein selectively expressed on natural killer cells. J Exp Med 1993; 178:2023-2033.
40. Carbone E, Ruggiero G, Terrazzano G, Palomba C, Manzo C, Fontana S, Spits H, Karre K, Zappacosta S: A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J Exp Med 1997; 185: 2053-2060.
41. Meyer T, Amaya M, Desai H, Robles-Carrillo L, Hatfield M, Francis JL, Amirkhosravi A: Human platelets contain and release TWEAK. Platelets 2010; 21:571-574.
42. Otterdal K, Smith C, Oie E, Pedersen TM, Yndestad A, Stang E, Endresen K, Solum NO, Aukrust P, Damas JK: Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes. Blood 2006; 108: 928-935.
43. Liu DM, Yan JC, Wang CP, Chen GH, Ding S, Liu PJ, Du RZ: The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome. Clin Chim Acta 2008; 397: 22-26.
44. Dybkaer K, Iqbal J, Zhou G, Geng H, Xiao L, Schmitz A, d'Amore F, Chan WC: Genome wide transcriptional analysis of resting and IL2 activated human natural killer cells: gene expression signatures indicative of novel molecular signaling pathways. BMC Genomics 2007; 8:230.
45. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, Hurst S, Danilenko D, Li J, Filvaroff E, Yang B, Daniel D, Ashkenazi A: TWEAK attenuates the transition from innate to adaptive immunity. Cell 2005; 123: 931-944.
46. Placke T, Kopp HG, Salih HR: Glucocorti-coid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation. Clin Dev Immunol 2010; 2010: 239083.
47. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A: Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001; 98:3352-3357.
48. Betz SA, Foucar K, Head DR, Chen IM, Willman CL: False-positive flow cytometric platelet glycoprotein IIb/IIIa expression in myeloid leukemias secondary to platelet adherence to blasts. Blood 1992; 79: 2399-2403.
49. Baltz KM, Krusch M, Bringmann A, Brossart P, Mayer F, Kloss M, Baessler T, Kumbier I, Peterfi A, Kupka S, Kroeber S, Menzel D, Radsak MP, Rammensee HG, Salih HR: Cancer immunoediting by GITR (glucocor-ticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J 2007; 21:2442-2454.
50. Baltz KM, Krusch M, Baessler T, Schmiedel BJ, Bringmann A, Brossart P, Salih HR: Neutralization of tumor-derived soluble gluco-corticoid-induced TNFR-related protein ligand increases NK cell anti-tumor reactivity. Blood 2008; 112: 3735-3743.
51. Placke T, Kanz L, Salih HR, Kopp HG: Pseu-doexpression of glucocorticoid-induced TNF-related (GITR) ligand upon coating of cancer cells by platelets impairs NK cell antitumor reactivity. Blood 2010; 116:3193.
52. Placke T, Kopp HG, Schaller M, Jung G, Kanz L, Salih HR: Transfer of MHC class I by coating platelets enables tumor cells to evade NK cell immune surveillance by conferring a 'pseudo self' phenoty pe. Blood 2010; 116:583.
53. Das D, Arber N, Jankowski JA: Chemopre-vention of colorectal cancer. Digestion 2007; 76: 51-67.
54. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN: Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-2129.
55. Coppinger JA, O'Connor R, Wynne K, Flanagan M, Sullivan M, Maguire PB, Fitzgerald DJ, Cagney G: Moderation of the platelet releasate response by aspirin. Blood 2007; 109:4786-4792.